Hypothesis

Lipid peroxidation‑derived aldehydes (e.g., 4‑HNE, acrolein) form stable covalent adducts on lysine residues of core histones, directly altering chromatin accessibility and establishing a self‑reinforcing epigenetic program that drives genomic instability, cellular senescence, mitochondrial dysfunction, and inflammaging. This carbonyl‑adduct epigenetic lock acts as an upstream controller of the aging hallmarks, rather than a parallel symptom.

Mechanistic Rationale

1. Adduct Formation on Histones – Reactive lipid enals preferentially target nucleophilic lysines in histone tails (H3K9, H3K27, H4K12) producing Michael‑addition products that resist standard deacetylase activity.[1]
2. Epigenetic Consequences – Adduct‑modified histones recruit HDACs and hinder HAT binding, leading to localized heterochromatin formation at promoters of DNA‑repair genes (e.g., BRCA1, OGG1) and mitochondrial biogenesis regulators (PGC‑1α, TFAM). Simultaneously, adducts at inflammatory gene promoters (e.g., IL6, TNFα) impede repressor complexes, favoring transcription.[2]
3. Feedback Loop – Heterochromatin at DNA‑repair loci increases γH2AX accumulation, raising nuclear ROS and further lipid peroxidation. Reduced PGC‑1α expression lowers mitochondrial oxidative capacity, amplifying ROS production and aldehyde generation.[3]
4. Phenotypic Spread – The epigenetic state is semi‑stable through cell divisions, propagating senescence‑associated secretory phenotype (SASP) and metabolic dysfunction to progeny cells, thereby linking the four hallmarks in a causal chain.

Testable Predictions

• Prediction 1: Cells treated with a lipid peroxidation inhibitor (e.g., ferrostatin‑1) or overexpressing aldehyde dehydrogenase 2 (ALDH2) will show reduced histone‑carbonyl adduct levels (detected by adduct‑specific immunoblotting or mass spectrometry) and concomitant increases in H3K9ac/H3K27ac at DNA‑repair and mitochondrial promoters.[1][2]
• Prediction 2: CRISPR‑knockin of a lysine‑to‑arginine mutant at H3K9 (preventing adduct formation) will rescue γH2AX foci, restore OXPHOS capacity, and suppress SASP cytokine secretion even under high oxidative stress.[3]
• Prediction 3: In vivo, mice with liver‑specific ALDH2 overexpression will exhibit delayed onset of multiple age‑related phenotypes (telomere attrition, senescent cell burden, mtDNA copy loss, circulating IL‑6) compared with wild‑type controls, correlating with lower hepatic histone‑carbonyl adduct burden.[4]

Experimental Approach

1. In vitro: Human fibroblasts exposed to low‑dose menadione to induce lipid peroxidation. Treat with ferrostatin‑1, ALDH2‑AAV, or vehicle. Quantify histone adducts via dot‑blot with anti‑4‑HNE‑lysine antibody, perform ChIP‑seq for H3K9ac/H3K27ac, and measure senescence (SA‑β‑gal), mitochondrial respiration (Seahorse), and cytokine ELISA.
2. Genetic: Generate H3K9R knock‑in fibroblast line using CRISPR‑HDR. Repeat oxidative challenge and assess the same readouts.
3. In vivo: Use AAV8‑ALDH2 to target liver in 12‑month‑old C57BL/6 mice. After 6 months, evaluate histone adducts, γH2AX in hepatocytes, mitochondrial ROS (MitoSOX), senescence markers (p16^INK4a^), and serum inflammaging cytokines. Compare to AAV‑control.

Falsifiability

If reducing lipid peroxidation or blocking histone adduct formation fails to concomitantly improve DNA‑repair gene expression, mitochondrial function, and inflammaging across multiple tissues, the hypothesis that carbonyl‑adduct epigenetics is a singular upstream controller would be refuted. Conversely, a coordinated rescue would support the idea that targeting this modification can modulate the aging program as a whole.